Insulin‐like growth factor (IGF)‐I and IGF‐binding protein‐3 serum levels in relapsing–remitting and secondary progressive multiple sclerosis patients
R Lanzillo, C Di Somma, M Quarantelli… - European journal of …, 2011 - Wiley Online Library
European journal of neurology, 2011•Wiley Online Library
Background: Insulin‐like growth factor (IGF)‐I has a role in remyelination, and insulin‐like
growth factor‐binding protein‐3 (IGFBP‐3) might reduce its bioavailability. A role of IGFBP‐3
in multiple sclerosis (MS) progression was hypothesized in patients with primary progressive
(PP) MS. Objective: To evaluate serum levels of IGF‐I and IGFBP‐3 in patients with
relapsing–remitting (RR) and secondary progressive (SP) MS and their correlations with
disease activity and progression. Methods: Sixty‐three (41 RR and 22 SP)'naive'MS patients …
growth factor‐binding protein‐3 (IGFBP‐3) might reduce its bioavailability. A role of IGFBP‐3
in multiple sclerosis (MS) progression was hypothesized in patients with primary progressive
(PP) MS. Objective: To evaluate serum levels of IGF‐I and IGFBP‐3 in patients with
relapsing–remitting (RR) and secondary progressive (SP) MS and their correlations with
disease activity and progression. Methods: Sixty‐three (41 RR and 22 SP)'naive'MS patients …
Background: Insulin‐like growth factor (IGF)‐I has a role in remyelination, and insulin‐like growth factor‐binding protein‐3 (IGFBP‐3) might reduce its bioavailability. A role of IGFBP‐3 in multiple sclerosis (MS) progression was hypothesized in patients with primary progressive (PP) MS.
Objective: To evaluate serum levels of IGF‐I and IGFBP‐3 in patients with relapsing–remitting (RR) and secondary progressive (SP) MS and their correlations with disease activity and progression.
Methods: Sixty‐three (41 RR and 22 SP) ‘naive’ MS patients and 60 age‐matched healthy controls were enrolled. Patients were assessed through clinical [Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), number of relapses] and laboratory investigations. IGF‐I and IGFBP‐3 were measured by ELISA.
Results: Levels of IGF‐I and IGFBP‐3 were similar in the two MS groups. IGFBP‐3 levels were higher in patients with MS than in controls (P < 0.001), with a reduction in IGF‐I/BP3 ratio (P < 0.001). Patients showing IGFBP‐3 levels higher than 2SD of the normal population had a higher EDSS (mean EDSS 3.7 vs. 2.8, P = 0.021). MSSS was not related to IGF‐I or IGFBP‐3 serum levels.
Conclusions: Our patients showed high IGFBP‐3 serum levels respect to controls and higher serum levels were associated with a higher EDSS, despite of comparable disease duration. Therefore, MS and higher disability seem to be associated with a reduction in bioavailability of IGF‐I. MSSS score was not related to IGFBP‐3 levels, suggesting that IGFBP‐3 might not have the pathogenetic role previously suggested for PP MS, in the mechanism of progression in the SP form of disease.
Wiley Online Library